2010 Comment Letters

Below is a listing of AACC's most recent comment letters. If you have questions regarding AACC's positions, please contact AACC Government Affairs at (800) 892-1400.

12/08/10 AACC provided comments to the FDA regarding its efforts to the streamline the regulatory review process for medical devices.
   
12/03/10 AACC joined with other health care groups in opposing CMS’s decision to require a physician’s signature on a requisition to get reimbursed under Medicare.
   
12/01/10 AACC joined with other health care groups in writing legislators in support of allowing independent clinical laboratories to bill Medicare directly for certain services provided to hospital patients.
   
10/06/10 AACC submitted comments to the FDA in regards to the agency’s oversight of laboratory developed tests
   
09/21/10 AACC submitted comments to the FDA regarding its proposed changes to the 510(k) review process
   
09/15/10 AACC joined with other health care providers in providing comments to the FDA regarding laboratory developed tests
   
09/14/10 AACC joined with other health care  providers in writing to Congress in opposition to the 1099 reporting requirement included in the health care reform statute
   
08/20/10 AACC joined with other health care groups in opposing CMS’s recommendation that clinical laboratories obtain a physician’s signature on each test requisition
   
07/14/10 AACC submitted comments to the FDA in regards to the agency’s oversight of laboratory developed tests
   
07/14/10 AACC wrote to the FDA Council on Medical Device Innovation urging that the De Novo process be utilized to clear low risk therapeutic drug monitoring devices
 
07/14/10 AACC wrote to the Institute of Medicine urging that it address the De Novo process as part of its report on the FDA’s 510(k) process 
 
04/29/10 AACC joined with other health care groups in opposing H.R. 5037, the Federal Research Public Access Act, which would require private sector journal articles that receive federal funding be released free to the public within six months of publication
 
04/02/10 AACC and NACB wrote to the FDA providing input on Agency's efforts to improve the clinical accuracy of blood glucose monitors
 
03/15/10 AACC joined with the Friends of AHRQ Coalition in supporting an increase in the Agency's comparative effectiveness budget
 
02/25/10 AACC wrote to the FDA offering suggestions on how to revise the 510(k) clearance process
 
02/24/10 AACC wrote to key legislators, such as Reb David Obey (D-WI), supporting continued funding for the National Children's Study
 
01/28/10 AACC joined with other laboratory groups in writing to House and Senate leaders in support of allowing independent clinical laboratories to bill Medicare directly for certain services provided to hospital patients
 
01/14/10 AACC wrote to House and Senate leaders urging them to keep AHRQ as the lead federal agency overseeing comparative effectiveness research 
 
01/07/10 AACC joined with other laboratory groups in writing to House and Senate leaders opposing cuts in laboratory reimbursement as part of health care reform
Page Access: